TOKYO, Oct 29 (Reuters) - Takeda Pharmaceutical Co Ltd (4502.T: Quote, Profile, Research) said on Monday that U.S. health authorities had recommended that it stop some clinical trials of its cholesterol-lowering TAK-475, a key drug candidate for the company.
